cagrilintide phase 2 Updates in Medicine | π¬ REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio π₯ 3a RCT in 1206 adults with T2D (BMI β₯27, HbA1c 7β10%) π HCPLive - CagriSema, a fixed
HCPLive CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and T2D in the Phase Cagrilintide Cagrilintidesemaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double blind, randomised, controlled, phase 3 study The Lancet Diabetes & Endocrinology Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications
Pay in 4 interest-free payments of $6.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12

00125-7/asset/85fa7e17-4785-4f71-9b61-806d7ecb7b4a/main.assets/gr2_lrg.jpg)
